Author:
Hino Christopher,Pham Bryan,Gray Austin L.,Wang Jun,Castillo Dan Ran,Akhtari Mojtaba,Liu Yan
Abstract
Mantle cell lymphoma (MCL) is a rare and aggressive non-Hodgkin’s B cell lymphoma characterized by the translocation t(11;14) (q13;32) and overexpression of CCND1. MCL is immunophenotypically identified as CD20+, CD5+, CyclinD1+, CD43+, CD10−, BCL6−, and CD23−. It is often distinguished from B cell lymphomas of germinal center cell origin by the absence of CD10 expression. Here we report the unique clinicopathologic features of a patient with CD10+ MCL with gastrointestinal involvement and review current literature identifying this unique immunophenotype.
Subject
Cancer Research,Oncology,General Medicine,Pathology and Forensic Medicine
Reference31 articles.
1. Mantle Cell Lymphoma: 2019 Update on the Diagnosis, Pathogenesis, Prognostication, and Management;Jain;Am J Hematol,2019
2. US Lymphoid Malignancy Statistics by World Health Organization Subtypes: 2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes;Teras;CA Cancer J Clin,20162016
3. Mantle Cell Lymphoma: Presenting Features, Response to Therapy, and Prognostic Factors;Bosch;Cancer,1998
4. Mantle-cell Lymphoma;Campo;Semin Hematol,1999
5. Genetic and Molecular Pathogenesis of Mantle Cell Lymphoma: Perspectives for New Targeted Therapeutics;Jares;Nat Rev Cancer,2007